Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.
Business Model:
Revenue: $11.8M
Employees: 11-50
Lutonix was acquired by
C. R. Bard.
The acquisition happend on 2011-12-20.
Details of the transaction were not public
Address: 7351 Kirkwood Ln N
City: Maple Grove
State: MN
Zip: 55369
Country: US
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.
Contact Phone:
+17634452352
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2007 | Series A | $5M | 12/2010 | Series C | $10M | 10/2008 | Series B | 4 | $20M |
Delphi Ventures U.S. Venture Partners RiverVest Versant Ventures Versant Ventures Delphi Ventures U.S. Venture Partners RiverVest Versant Ventures Versant Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|